Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial - PubMed
7 hours ago
- #immunotherapy
- #cervical cancer
- #clinical trial
- Cadonilimab plus chemotherapy with or without bevacizumab shows significant progression-free survival (PFS) and overall survival (OS) benefits in advanced cervical cancer.
- Subgroup analyses from the COMPASSION-16 phase 3 trial confirm consistent improvements across diverse patient profiles.
- Key subgroups analyzed include bevacizumab use, prior chemoradiotherapy, PD-L1 CPS, metastatic disease, platinum use, and age.
- Median follow-up was 25.6 months, with hazard ratios (HRs) favoring cadonilimab in all subgroups for PFS.
- The study also reports prolonged overall survival with the addition of cadonilimab.
- Dual primary endpoints were PFS (assessed by BICR) and OS, with objective response rate as a secondary endpoint.